Weekly Digest - June 2025
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - June 2025
17 June 2025: Boan receives FDA IND clearance for Its CD228-directed ADC
- Boan Biotech received FDA clearance to begin clinical trials in the U.S. for BA1302, a novel CD228-targeting ADC for treating various solid tumors, including sqNSCLC and pancreatic cancer, for which it previously received Orphan Drug Designation
- Preclinical studies showed BA1302 had strong anti-tumor effects, high internalization, and a favorable safety profile compared to other MMAE-based ADCs, with potential as a monotherapy or in combination therapies
- Boan Biotech is advancing its ADC platform, with BA1302 and Claudin18.2 ADC in clinical trials, and several additional ADCs and bispecific ADCs in preclinical development, aiming to expand global cancer treatment options
